Pfizer Inc said its blockbuster pain drug, Lyrica, had failed to show benefit in patients suffering from a type of post-traumatic nerve pain, in a late-stage study.
The drug did not lead to pain reduction in patients compared with a placebo, the company said on Wednesday.
Currently, there is no approved treatment in the United States for post-traumatic neuropathic pain.
Lyrica, which generated $1.22 billion in sales in the third quarter, is already approved to treat nerve pain associated with diabetes, shingles, spinal cord injury and fibromyalgia.
Note: Lyrica is also known as Pegabalin.